DEBM_CompanyBanner_InnovationFund_LG

Digital Health Investment


bringing
your
vision
to life

Fuel your digital health ambition with strategic funding

Bold healthtech ideas can change the way disease is managed and treated. As Debiopharm’s strategic corporate fund, we invest in digital health, smart data & innovative tech start-ups. Are you an entrepreneur seeking funding for your digital health start-up?  Let us help you take your ambition to the next level.

Company stage
Late pilot or early commercial
Investment round
Series A and B
Our typical initial investment
$3M - 5M
Discover our investment criteria
Investment porfolio

Current and past Investments

Debiopharm-Investment-Portfolio

Discover the success stories of entrepreneurs like you

Discover
Our latest portfolio news
June 18, 2021

Debiopharm interviewed by Biotech Finances to talk about our evergreen fund

Read more
June 7, 2021

Voluntis on receiving FDA 510(K) Clearance and expanding

Read more
Latest news
Our mission

Support companies like yours

Your technologies and business models aim to make drug development and treatment more patient centric, accessible and affordable?

We seek startups like yours that improve the cancer patient journey and re-imagine how clinical trials are conducted.

We are also interested in digital health companies focused on bacterial infections.

You will have access to our expertise situated at the crossroads of technological solutions and pharmaceutical know-how which include: Drug development, Regulatory processes, Reimbursement and market access, Management of health-tech companies.

With the aim to

  • Increase the pace of your scale-up process with strategic guidance and piloting,
  • Provide long-term, evergreen funding with multiple financing rounds,
  • Work along with your team to achieve a positive return on investment for all stakeholders,
  • Drive our portfolio investments towards successful exits.

Our track record for your entrepreneurial success

  • Lead investor in 19 out of 25 last investment rounds
  • USD 120 million invested since 2008
  • Portfolio companies have achieved 10 FDA clearances, 13 CE marks & 2 IPOs and 4 trade exits
  • Cumulative equity raised accross companies: over USD 500 million
Share your investment deck
Debiopharm-Tanja-Dowe
Leadership team

Discover the people who guide and bring long-term vision to the digital health investments at Debiopharm

Meet our team
Are you an entrepreneur seeking funding

Discover how we can help you take your ambition to the next level

Discover how we can help you